Table 2.
ORR according to RECIST 1.1 and PERCIST 1.0 at follow-up 1, 2 and 3; n = 10
| Pat_no | Follow-up 1* | Follow-up 2 | Follow-up 3 | BOR | ||||
|---|---|---|---|---|---|---|---|---|
| RECIST 1.1 | PERCIST 1.0 | RECIST 1.1 | PERCIST 1.0 | RECIST 1.1 | PERCIST | RECIST 1.1 | PERCIST 1.0 | |
| 10 | PD | SMD | PD | SMD | PD | PMD | PD | SMD |
| 11 | PD | NA | PD | PMD | PD | PMD | PD | PMD |
| 12 | PD | PMD | NA | NA | NA | NA | PD | PMD |
| 13 | PD | SMD | PD | PMD | NA | NA | PD | SMD |
| 14 | PD | PMD | PD | PMD | NA | NA | PD | PMD |
| 15 | PD | PMD | PD | PMD | NA | NA | PD | PMD |
| 16 | PD | PMD | PD | PMD | PD | PMD | PD | PMD |
| 17 | SD | PMR | PR | PMD | PR | PMD | PR | PMR |
| 18 | PD | SMD | PD | SMD | PD | SMD | PD | SMD |
| 19 | PD | SMD | PD | NA | NA | NA | PD | SMD |
| Comparisons | ||||||||
|---|---|---|---|---|---|---|---|---|
| n | 9 | 8 | 5 | 10 | ||||
| Cohen’s κ | 0 | 0.091 | 0.111 | 0.134 | ||||
| P-value | 0.037 | 1 | 1 | 1 | ||||
Follow-up 1 corresponded to around 3 months after the treatment start, follow-up 2–6 months and follow-up 3–9 months after treatment start. BOR – best overall response. Cohen’s k and Wilcoxon signed-rank tests were calculated to determine agreements and differences between the two criteria protocols.
NA, not available; PD, progressive disease; PMD, progressive metabolic disease; PMR, partial metabolic response; PR, partial response; SD, stable disease; SMD, stable metabolic disease.